Osteoarthritis News and Research

Latest Osteoarthritis News and Research

REGN reports net loss of $30.5M for first-quarter 2010

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the first quarter of 2010. The Company reported a net loss of $30.5 million, or $0.38 per share (basic and diluted), for the first quarter of 2010 compared with a net loss of $15.4 million, or $0.19 per share (basic and diluted), for the first quarter of 2009.

30 Apr 2010

Whole-genome analysis may play future role in clinical medicine: Study

Scientists at Stanford and Harvard Universities collaborated to assess the clinical usefulness of analyzing a patient's full genome for disease risks and unusual drug responses. The work brings closer to reality the concept that whole-genome sequencing might one day play a clinical role.

30 Apr 2010

Adolor's ENTEREG first-quarter net product sales increases to $5.3 million

Adolor Corporation today reported a net loss of $9.6 million, or $(0.21) per basic and diluted share, for the three months ended March 31, 2010, compared to a net loss of $13.2 million, or $(0.28) per basic and diluted share, for the three months ended March 31, 2009.

29 Apr 2010

ViroPharma initiates multi-dose Phase 2 study of Cinryze in patients with HAE

ViroPharma Incorporated today announced that it has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous versus intravenous administration of Cinryze (C1 esterase inhibitor [human)] in 24 adolescents and adult subjects with hereditary angioedema.

27 Apr 2010

Nuvo Research's PENNSAID now available in U.S. pharmacies

Nuvo Research Inc., a drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced that PENNSAID(R) (diclofenac sodium topical solution) 1.5% w/w, is now available by prescription in U.S. pharmacies.

27 Apr 2010

Phase 2b clinical study initiated to evaluate GI safety of LT-NS001

Logical Therapeutics, Inc., a Waltham, Mass.-based biotechnology company announced today the initiation of a Phase 2b clinical study to evaluate the gastrointestinal safety of its investigational drug LT-NS001 (naproxen etemesil). The study will compare the cumulative rate of gastric ulcers vs. Naprosyn after 12 weeks of treatment.

27 Apr 2010

Covidien introduces PENNSAID to the U.S. market

Covidien, a leading global provider of healthcare products, has introduced PENNSAID (diclofenac sodium topical solution) 1.5% w/w to the U.S. market. PENNSAID is the only FDA-approved topical non-steroidal anti-inflammatory drug in a vehicle solution containing dimethyl sulfoxide, a known penetrating agent. It is indicated for treatment of the signs and symptoms of osteoarthritis of the knee(s).

26 Apr 2010

Prevention and nonsurgical treatment options to prevent low back pain and protect spine

Back and neck problems can be caused by a herniated disc, spinal stenosis, injury, strain or osteoarthritis. "Although more than 75 percent of Americans will experience some back pain during their lifetime, about 90 percent of cases are resolved without surgery," stated John K. Ratliff, MD, FACS, a Philadelphia spine surgeon and American Association of Neurological Surgeons spokesperson.

24 Apr 2010

New ways for earlier diagnosis of osteoarthritis

Researchers at King's College London's Department of Twin Research and Genetic Epidemiology, based at St Thomas' Hospital have discovered new ways of measuring biological markers in the blood which could be used to diagnose osteoarthritis earlier.

23 Apr 2010

Abbott's first-quarter worldwide pharmaceutical sales increases by 12.9%

Abbott today announced financial results for the first quarter ended March 31, 2010.

21 Apr 2010

New nanotechnology biomedical therapy for joint injuries

Dr. Nirav A. Shah, MD, an orthopaedic sports medicine surgeon affiliated with Palos Community Hospital is the first to design a new nanotechnology biomedical therapy that promotes the growth of new, stronger cartilage to aid in the treatment of joint injuries.

16 Apr 2010

Moving is the best medicine for arthritic pain

The burden of arthritis is greater for African Americans and Hispanics, despite lower prevalence among these groups according to a Centers for Disease Control and Prevention (CDC) report published in the May issue of Preventing Chronic Disease.

16 Apr 2010

Articulinx closes $10M Series B financing round

Articulinx, Inc., a medical device company developing a novel minimally-invasive approach for the treatment of osteoarthritis, announced today the closing of a $10M Series B financing led by US Venture Partners (USVP).

15 Apr 2010

ConforMIS' iUni G2 patient-specific knee replacement system receives CE Mark certification

ConforMIS, Inc. announced today that the iUni® G2 has received CE Mark certification, providing regulatory approval for ConforMIS to begin the sale of this products throughout the European Union. The iUni G2 is the next generation of ConforMIS' revolutionary patient-specific knee replacement system, and remains the only patient-specific unicompartmental knee resurfacing implant on the market.

15 Apr 2010

XOMA expands anti-inflammatory antibody intellectual property portfolio

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Patent and Trademark Office has issued two new patents that significantly expand the company's intellectual property portfolio relating to its anti-inflammatory antibody, XOMA 052, that targets interleukin-1 beta (IL-1 beta).

13 Apr 2010

Oceana Therapeutics, Q-Med submit Solesta PMA application for treatment of fecal incontinence

Oceana Therapeutics and Q-Med AB today announced the filing of a Premarket Approval (PMA) application with the U.S. Food and Drug Administration (FDA) for Solesta® for the treatment of Fecal (or Bowel) Incontinence, a largely unsatisfied medical need afflicting millions of Americans.

12 Apr 2010

Meltdown Station provides educational material to help children learn healthy lifestyle skills

With the childhood obesity epidemic finally at the front line, first lady Mrs. Obama has taken the initiative to do something about it, but what is she doing? The first lady Mrs. Obama started the Let's Move! Initiative and stated in a press conference "that the goal of the program is to reverse the trend toward childhood obesity in one generation."

8 Apr 2010

AHRQ: Women accounted for nearly 60% of 39.4M admissions to U.S. hospitals in 2007

Women accounted for nearly 60 percent of the 39.4 million admissions to U.S. hospitals in 2007, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

7 Apr 2010

Leg length inequality linked to osteoarthritis: Study

A new study shows that arthritis in the knee is linked to the common trait of having one leg that is longer than the other. Whether or not leg length differential is a direct cause of osteoarthritis is not clear, but the findings may allow people to take preventive measures before the onset of the chronic and painful condition.

1 Apr 2010

Positive results from Phase 2 clinical trial of OMS103HP

Omeros Corporation today announced that a Phase 2 clinical trial of OMS103HP, its PharmacoSurgery™ product candidate for arthroscopy, demonstrated that patients treated with OMS103HP during arthroscopic knee meniscectomy surgery achieved statistically significant clinical benefits.

1 Apr 2010